Bristol Myers Squibb– tag –
-
Cellares Secures $327M in Series D Funding, Including ARK Invest, and Expands Major Manufacturing Agreements with Bristol Myers Squibb and Cabaletta Bio
AllSci USA Overview Cellares has extended its Series D financing to $327 million with a new $50 million investment, specifically aimed at scaling cell therapy manufacturing. As an Integrated Development and Manufacturing Organization (ID... -
The In Vivo CAR-T Race Heats Up: Big Pharma Acquisitions and Astellas’ Strategic Collaborations Signal a New Era in Cancer Therapy
Answers（アンサーズ） Japan Overview The global race to develop 'in vivo CAR-T therapy,' which generates CAR-T cells directly within the patient's body, is intensely accelerating as major pharmaceutical companies invest heavily. This inn... -
Pharmaceutical Manufacturing Realignments Create Expansion Opportunities for CDMOs: GSK, BMS, Sanofi Divest Facilities
Pharmaceutical Technology USA Overview A significant reconfiguration is underway in the pharmaceutical manufacturing sector, with major CDMOs acquiring production facilities from pharmaceutical companies. Samsung Biologics, Rois, and Adr...
12